BioArctic announces positive topline results of BAN2401 Phase 2b at 18 months in early Alzheimer’s Disease

The full 18 month analysis of the 856 patient BAN2401 Phase 2b clinical study in early Alzheimer’s disease demonstrated statistically significant and dose-dependent slowing in clinical decline and reduction of amyloid beta accumulated in the brain.

The release as fetched from its publisher. bioarctic.com ↗